At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Panitumumabdrug
Likely dose
Panitumumab 9 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
In Brief
A Phase 2 clinical trial evaluating Panitumumab for Cancer and 8 related conditions. Completed, enrolled 52 participants.
Detailed Summary
To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Carcinoma, Head and Neck Cancer, Metastases, Metastatic Cancer, Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck, Oncology, Squamous Cell Carcinoma, Tumors
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartOct 2007
Primary CompletionDec 2010
Study CompletionNov 2017
TodayJul 2026
First PostedMar 12, 2007
Enrollment StartOct 30, 2007
Primary CompletionDec 15, 2010
Study CompletionNov 29, 2017
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 19.3 years ago
Interventions
Panitumumabdrug
Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.